Dr. Donald R. Johns joined Biogen from Novartis Institutes for BioMedical Research as vice president to lead Biogen’s amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub), a new unit established in development of novel therapies for ALS by integrating research with clinical development.